Bloomberg Technology The only daily news program focused exclusively on technology, innovation and the future of business from San Francisco.
The Breakdown: Evergrande Once one of China’s most successful developers, Evergrande has been labeled a defaulter and is more than $300 billion in debt. Now it's racing to restructure as bondholders warn of possible enforcement action.
Subscriber OnlyOpinionMax NisenEli Lilly's Blockbuster Resurrection Story Has HolesIts arthritis drug's new lease on FDA life apparently comes with conditions.Photographer: Michael NagleByMax Nisen+FollowApril 19, 2018, 6:09 PM UTCEli Lilly & Co.'s arthritis drug Olumiant -- a would-be blockbuster developed with Incyte Corp. -- miraculously emerged from the graveyard in August after the FDA un-rejected the medicine and agreed to consider it for approval. But rising from the dead is not so simple.
